Should You Buy The Botox Maker Over Johnson & Johnson Stock?

Even if we look at a longer time frame, AbbVie fares better, with its sales rising at an average annual growth rate of 21% to $58 billion in 2022, compared to $33 billion in 2019, while J&J’s saw its revenue rise at an average annual rate of just 5% to $95 billion in 2022, compared to $82 billion...